Chemed (CHE)
(Delayed Data from NYSE)
$561.65 USD
+2.00 (0.36%)
Updated May 3, 2024 04:00 PM ET
After-Market: $561.66 +0.01 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$561.65 USD
+2.00 (0.36%)
Updated May 3, 2024 04:00 PM ET
After-Market: $561.66 +0.01 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth B Momentum C VGM
Zacks News
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on strength in its key product lines and raised 2021 guidance.
CVS Health (CVS) Installs Time-Delay Safes in Texas Pharmacies
by Zacks Equity Research
CVS Health's (CVS) time-delay safes reduce theft and diversion of opioid medications and boost the security of stores, creating a safe environment for patients and staff.
Alcon (ALC) Surgical Arm Grows Amid Global Trade Disruption
by Zacks Equity Research
Segment wise, within Alcon's (ALC) Surgical arm, the portfolio of advanced technology intraocular lenses is driving increased penetration rates of ATIOLs.
Illumina's (ILMN) New Alliance to Accelerate Genomics in China
by Zacks Equity Research
Illumina's (ILMN) Genomics Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics.
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher (TMO) on strength in end markets and raised 2021 guidance.
Veeva Systems (VEEV) Digital Tools Boost Patient Engagement
by Zacks Equity Research
Veeva Systems' (VEEV) enhancements in digital tools incorporate new ways for seamless communication among healthcare providers and field teams.
Zimmer Biomet's (ZBH) Recovery Slows in Americas Amid Pandemic
by Zacks Equity Research
The third quarter brings greater COVID-related pressure than expected for Zimmer Biomet (ZBH).
CVS Health's (CVS) New Measures to Boost Omnichannel Health
by Zacks Equity Research
CVS Health's (CVS) new measures will support its strategy of making health care more affordable, accessible and convenient for consumers.
LabCorp (LH) to Expand Nonclinical Development With New Buyout
by Zacks Equity Research
LabCorp's (LH) acquisition of Toxikon can expand its full-service drug development and medical device solutions portfolio.
Phibro (PAHC) Sales Hurt by Staffing Shortage Amid Pandemic
by Zacks Equity Research
Internationally, Phibro (PAHC) is registering growth in nutritional specialties driven by strong sales of dairy products.
Masimo (MASI) Reports SedLine's Psi & DSA Parameter Findings
by Zacks Equity Research
The study findings show that monitoring with Masimo (MASI) SedLine Brain Function Monitoring parameters during CEA surgery can reduce the risk of postoperative delirium.
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
by Zacks Equity Research
Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.
Thermo Fisher (TMO) New Facility to Advance Lab Products Supply
by Zacks Equity Research
Thermo Fisher's (TMO) new manufacturing facility will help the United States meet demand surges for vital laboratory products.
Abbott (ABT) Introduces New Next-Generation Infant Formula
by Zacks Equity Research
Abbott's (ABT) Similac 360 Total Care contains five different HMOs, similar to human breast milk, to support the health and development of an infant.
SmileDirectClub (SDC) Introduces Treatment Planning Software
by Zacks Equity Research
SmileDirectClub's (SDC) SmileOS will enable its affiliated network of state-licensed doctors to treat more patients, better predict tooth movements and visualize patients' treatment.
Abbott (ABT) Scales to a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Diabetes Care and Diagnostics businesses is driving the top line for Abbott (ABT).
Cardiovascular Systems (CSII) Business Down on COVID Resurgence
by Zacks Equity Research
According to Cardiovascular Systems (CSII), the resurgence of COVID-19 and the related staffing shortages are disrupting referral patterns and having the largest impact on elective procedures.
Walgreens (WBA), VillageMD Plan to Expand Into Tampa, Florida
by Zacks Equity Research
Walgreens (WBA), VillageMD to open 20 new Village Medical at Walgreens primary care practices in the Tampa area to improve access to overall care for patients with chronic conditions.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) owing to better-than-anticipated results in the third quarter and strength in the Vascular business.
Omnicell (OMCL) Inks New Deal to Manage Controlled Substances
by Zacks Equity Research
Omnicell (OMCL), Fresenius Kabi collaborate to offer safe and efficient dispensing of controlled substances across hospitals and health systems in the United States.
Here's Why You Should Add Chemed (CHE) to Your Portfolio Now
by Zacks Equity Research
Robust performance across the Roto-Rooter segment and sequential growth in VITAS admissions are driving the top line for Chemed (CHE).
IDEXX (IDXX) CAG Placement Grows Globally, LPD Disappoints
by Zacks Equity Research
IDEXX' (IDXX) global Reference Lab businesses are robust driven by high same-store volume growth with strong gains across testing categories.
Quidel (QDEL) Q3 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Quidel (QDEL) records a strong Q3 performance despite lower revenues from two of its product categories.
Allscripts' (MDRX) Q3 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.
Accuray (ARAY) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Accuray (ARAY) registers growth in both Service and Product revenues during fiscal Q1.